Bharat Biotech: Celebrating Three Decades of Vaccine Innovation and Global Health Impact

Bharat Biotech marks its 30th anniversary, celebrating its global health contributions and unveiling a commemorative logo. Founded by Krishna Ella and Suchitra Ella, the company has pioneered affordable vaccine innovations, contributing to India's position as a major player in global immunization with a focus on equitable healthcare for emerging nations.

Bharat Biotech, a leading vaccine innovator, is celebrating 30 years of scientific advancements and significant public health contributions. Founded by Krishna and Suchitra Ella, the company marked this milestone by unveiling a special logo at its Genome Valley facility. The event also initiated a series of year-long initiatives showcasing its journey.

Established in 1996, Bharat Biotech has played a pivotal role in positioning India as a trusted supplier of affordable, high-quality vaccines globally. Its portfolio includes vaccines for Rotavirus, Japanese Encephalitis, and innovative solutions against infectious diseases that affect emerging countries. The company's commitment to affordable healthcare is reflected in its groundbreaking Rotavirus vaccine, available at just US$1 per dose.

During the COVID-19 crisis, Bharat Biotech swiftly developed COVAXIN®, India's first indigenous vaccine, illustrating its scientific agility and India's self-reliance. Expanding its research into cell and gene therapies through Nucelion Therapeutics, the company continues to advance biotech innovations, cementing its status as a global vaccine powerhouse with facilities across India.

(With inputs from agencies.)